What comes after docetaxel?

被引:0
|
作者
Ohlmann, C. -H. [1 ]
Stoeckle, M. [1 ]
机构
[1] Univ Klinikum Saarlandes, Klin Urol & Kinderurol, D-66421 Homburg, Germany
来源
UROLOGE | 2010年 / 49卷 / 01期
关键词
Castration-resistant prostate cancer; Chemotherapy; Docetaxel resistance; Hormonal treatment; Targeted therapy; REFRACTORY PROSTATE-CANCER; MITOXANTRONE PLUS PREDNISONE; PHASE-II TRIAL; IMATINIB MESYLATE; CHEMOTHERAPY; KETOCONAZOLE; CARBOPLATIN; ANTIANDROGEN; PROGRESSION; INHIBITORS;
D O I
10.1007/s00120-009-2146-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Chemotherapy with docetaxel represents the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC). In cases of progression after treatment with docetaxel no standard treatment recommendation exists since no treatment was able to show a survival benefit in clinical trials. This review focuses on available treatment options for patients with progressive CRPC and highlights promising treatments that are currently under investigation in clinical trials including abiraterone acetate and MDV3100.
引用
下载
收藏
页码:64 / 68
页数:5
相关论文
共 50 条